A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...